0001100397 false --10-31 2022 Q1 2025-11-30 0001100397 2021-11-01 2022-01-31 0001100397 2022-03-16 0001100397 2022-01-31 0001100397 2021-10-31 0001100397 ADXS:SeriesDConvertibleRedeemablePreferredStockMember 2022-01-31 0001100397 ADXS:SeriesDConvertibleRedeemablePreferredStockMember 2021-10-31 0001100397 2020-11-01 2021-01-31 0001100397 2020-10-31 0001100397 2021-01-31 0001100397 ADXS:SeriesDPreferredStockRedemptionMember 2022-01-31 0001100397 us-gaap:WarrantMember 2021-11-01 2022-01-31 0001100397 us-gaap:WarrantMember 2020-11-01 2021-01-31 0001100397 ADXS:SeriesDConvertableRedeemablePreferredStockMember 2021-11-01 2022-01-31 0001100397 ADXS:SeriesDConvertableRedeemablePreferredStockMember 2020-11-01 2021-01-31 0001100397 ADXS:StockOptionsMember 2021-11-01 2022-01-31 0001100397 ADXS:StockOptionsMember 2020-11-01 2021-01-31 0001100397 ADXS:RestrictedStockUnitsMember 2021-11-01 2022-01-31 0001100397 ADXS:RestrictedStockUnitsMember 2020-11-01 2021-01-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2021-11-01 2022-01-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2020-11-01 2021-01-31 0001100397 2021-03-01 2021-03-26 0001100397 2021-03-26 0001100397 2021-03-01 2021-03-25 0001100397 2021-03-25 0001100397 us-gaap:WarrantMember 2022-01-31 0001100397 us-gaap:WarrantMember 2021-10-31 0001100397 us-gaap:WarrantMember srt:MinimumMember 2022-01-31 0001100397 us-gaap:WarrantMember srt:MaximumMember 2022-01-31 0001100397 ADXS:EquityWarrantsMember 2021-10-31 0001100397 ADXS:EquityWarrantsMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:IPOMember 2022-01-31 0001100397 srt:MinimumMember 2021-06-03 0001100397 srt:MaximumMember 2021-06-03 0001100397 ADXS:WarrantLiabilityMember srt:MaximumMember 2021-01-31 0001100397 ADXS:WarrantLiabilityMember srt:MinimumMember 2021-01-31 0001100397 us-gaap:PrivatePlacementMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeOneMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeFourMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeFourMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeSixMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeSixMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeSixMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeSixMember 2021-11-01 2022-01-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:PrivatePlacementMember ADXS:InstitutionalInvestorsMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-01-31 0001100397 us-gaap:SeriesDPreferredStockMember us-gaap:PrivatePlacementMember ADXS:InstitutionalInvestorsMember 2022-01-31 0001100397 2022-01-01 2022-01-31 0001100397 us-gaap:SeriesDPreferredStockMember 2022-01-31 0001100397 us-gaap:MeasurementInputExercisePriceMember 2022-01-31 0001100397 us-gaap:MeasurementInputSharePriceMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-31 0001100397 us-gaap:PreferredStockMember 2020-10-31 0001100397 us-gaap:CommonStockMember 2020-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001100397 us-gaap:RetainedEarningsMember 2020-10-31 0001100397 us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0001100397 us-gaap:PreferredStockMember 2021-01-31 0001100397 us-gaap:CommonStockMember 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2021-01-31 0001100397 us-gaap:PreferredStockMember 2021-10-31 0001100397 us-gaap:CommonStockMember 2021-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0001100397 us-gaap:RetainedEarningsMember 2021-10-31 0001100397 us-gaap:PreferredStockMember 2021-11-01 2022-01-31 0001100397 us-gaap:CommonStockMember 2021-11-01 2022-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0001100397 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0001100397 us-gaap:PreferredStockMember 2022-01-31 0001100397 us-gaap:CommonStockMember 2022-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001100397 us-gaap:RetainedEarningsMember 2022-01-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2021-11-01 2022-01-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2020-11-01 2021-01-31 0001100397 srt:ChiefExecutiveOfficerMember 2022-01-31 0001100397 ADXS:DevelopmentLicenseAndSupplyAgreementMember ADXS:OSTherapiesMember 2020-04-29 2020-04-30 0001100397 ADXS:DevelopmentLicenseAndSupplyAgreementMember ADXS:OSTherapiesMember 2018-09-03 2018-09-04 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2022-01-31 0001100397 us-gaap:MoneyMarketFundsMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel1Member 2022-01-31 0001100397 us-gaap:FairValueInputsLevel2Member 2022-01-31 0001100397 us-gaap:FairValueInputsLevel3Member 2022-01-31 0001100397 us-gaap:FairValueInputsLevel1Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel2Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel3Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-01-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:PrivatePlacementMember 2021-10-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember 2021-10-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2021-11-01 2022-01-31 0001100397 ADXS:WarrantLiabilityMember 2021-11-01 2022-01-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember 2022-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ADXS:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended January 31, 2022

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission file number 001-36138

 

ADVAXIS, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware   02-0563870
(State or other jurisdiction of   (IRS Employer
incorporation or organization)   Identification No.)

 

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ   08852
(Address of principal executive offices)   (Zip Code)

 

(609) 452-9813
(Registrant’s telephone number)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   ADXS   OTCQX® Best Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such fling requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐   Accelerated Filer ☐
Non-accelerated Filer ☒   Smaller Reporting Company ☒
Emerging growth company ☐      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares of the registrant’s Common Stock, $0.001 par value, outstanding as of March 16, 2022 was 145,638,459.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page No.
     
PART I FINANCIAL INFORMATION 5
     
Item 1. Financial Statements (unaudited) 5
     
  Condensed Consolidated Balance Sheets 5
     
  Condensed Consolidated Statements of Operations 6
     
  Condensed Consolidated Statements of Cash Flows 7
     
  Notes to the Condensed Consolidated Financial Statements 8
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 25
     
Item 4. Controls and Procedures 25
     
PART II OTHER INFORMATION 25
     
Item 1. Legal Proceedings 25
     
Item 1A. Risk Factors 26
     
Item 6. Exhibits 26
     
SIGNATURES 28

 

2
 

 

CAUTIONARY NOTE REGARDING FORWARD LOOKING-STATEMENTS

 

This quarterly report on Form 10-Q (“Form 10-Q”) of Advaxis, Inc. (the “Company”) includes statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by the use of such terms as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or the negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned discovery and development of drug candidates, the strength and breadth of our intellectual property, our ongoing and planned preclinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our product candidates, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, our available cash, liquidity, prospects, growth and strategies, impacts of the ongoing coronavirus (COVID-19) pandemic, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect our industry or us.

 

By their nature, forward-looking statements involve risks and uncertainties because they relate to the occurrence and timing of events or circumstances, many of which are beyond the control of the Company. As a result of these, we cannot assure you that the forward-looking statements in this Form 10-Q will prove to be accurate. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Form 10-Q, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate, are consistent with the forward-looking statements contained in this Form 10-Q, they may not be predictive of results or developments in future periods.

 

3
 

 

Some of the material factors that we believe could cause actual results to differ from those anticipated or predicted include:

 

  ● the success and timing of our clinical trials, including patient accrual;
     
  ● our ability to obtain and maintain regulatory approval or reimbursement of our product candidates for marketing;
     
  ● our ability to obtain the appropriate labeling of our products under any regulatory approval;
     
  ● our ability to develop and commercialize our products;
     
  ● the successful development and implementation of our sales and marketing campaigns;
     
  ● the change of key scientific or management personnel;
     
  ● the size and growth of the potential markets for our product candidates and our ability to serve those markets;
     
  ● our ability to successfully compete in the potential markets for our product candidates, if commercialized;
     
  ● regulatory developments in the United States and foreign countries;
     
  ● new products, product candidates or new uses for existing products or technologies introduced or announced by our competitors and the timing of these introductions or announcements;
     
  ● market conditions in the pharmaceutical and biotechnology sectors;
     
  ● our available cash;
     
  ● the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;
     
  ● our ability to obtain additional funding;
     
  ● any outcomes from our review of strategic transactions and options to maximize stockholder value;
     
  ● the ability of our product candidates to successfully perform in clinical trials and to resolve any clinical holds that may occur;
     
  ● our ability to obtain and maintain approval of our product candidates for trial initiation;
     
  ● the performance of third-party manufacturers;
     
  ● our ability to identify license and collaboration partners and to maintain existing relationships;
     
  ● the performance of our clinical research organizations, clinical trial sponsors, clinical trial investigators and collaboration partners for any clinical trials we conduct;
     
  ● our ability to successfully implement our strategy;
     
  ● our ability to maintain the listing of our common stock on the OTCQX® Best Market (“OTCQX”); and
     
  ● the factors described in the “Risk Factors” section of the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2021 (the “2021 Annual Report on Form 10-K”), as updated and amended in other filings by the Company with the Securities and Exchange Commission (the “SEC”).

 

You should also read carefully the factors described in the “Risk Factors” section of the 2021 Annual Report on Form 10-K. Any forward-looking statements that we make in this Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Form 10-Q except as required by the federal securities laws.

 

This Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data.

 

4
 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

ADVAXIS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

  

January 31, 2022

   October 31, 2021 
   (Unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $36,480   $41,614 
Restricted cash   5,250    - 
Prepaid expenses and other current assets   1,386    1,643 
Total current assets   43,116    43,257 
           
Property and equipment (net of accumulated depreciation)   100    118 
Intangible assets (net of accumulated amortization)   3,238    3,354 
Operating right-of-use asset (net of accumulated amortization)   33    40 
Other assets   11    11 
           
Total assets  $46,498   $46,780 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $345   $87 
Accrued expenses   2,131    2,836 
Current portion of operating lease liability   29    28 
Preferred stock redemption liability   87    - 
Common stock warrant liability   1,127    4,929 
Total current liabilities   3,719    7,880 
           
Operating lease liability, net of current portion   5    12 
Total liabilities   3,724    7,892 
           
Contingencies – Note 10   -    - 
           
Series D convertible preferred stock- $0.001 par value; 1,000,000 shares authorized, issued and outstanding at January 31, 2022; Liquidation preference of $5,250 at January 31, 2022.   4,225    - 
           
Stockholders’ equity:          
Preferred stock, $0.001 par value; 4,000,000 and 5,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2022 and October 31, 2021.   -    - 
Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 shares issued and outstanding at January 31, 2022 and October 31, 2021.   146    146 
Additional paid-in capital   467,368    467,342 
Accumulated deficit   (428,965)   (428,600)
Total stockholders’ equity   38,549    38,888 
Total liabilities and stockholders’ equity  $46,498   $46,780 

 

The accompanying notes should be read in conjunction with the financial statements.

 

5
 

 

ADVAXIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(In thousands, except share and per share data)

 

   2022   2021 
   Three Months Ended
January 31,		 
   2022   2021 
         
Revenue  $-   $1,615 
           
Operating expenses:          
Research and development expenses   1,654    2,570 
General and administrative expenses   2,510    3,008 
Total operating expenses   4,164    5,578 
           
Loss from operations   (4,164)   (3,963)
           
Other income (expense):          
Interest income, net   1    1 
Net changes in fair value of derivative liabilities   3,802    (27)
Other (expense) income   (4)   12 
Net loss before income taxes   (365)   (3,977)
           
Income tax expense   -    - 
           
Net loss  $(365)  $(3,977)
           
Net loss per common share, basic and diluted  $(0.00)  $(0.05)
           
Weighted average number of common shares, basic and diluted   145,638,459    83,943,982 

 

The accompanying notes should be read in conjunction with the financial statements.

 

6
 

 

ADVAXIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(In thousands)

 

   2022   2021 
   Three Months Ended
January 31,		 
   2022   2021 
         
OPERATING ACTIVITIES          
Net loss  $(365)  $(3,977)
Adjustments to reconcile net loss to net cash used in operating activities:          
Share based compensation   26    236 
(Gain) loss on change in value of warrants   (3,802)   27 
Loss on disposal of property and equipment   -    12 
Abandonment of intangible assets   104    - 
Depreciation expense   18    192 
Amortization expense of intangible assets   70    67 
Amortization of right-of-use asset   7    195 
Change in operating assets and liabilities:          
Prepaid expenses, other current assets and deferred expenses   257    463 
Accounts payable and accrued expenses   (447)   394 
Deferred revenue   -    (165)
Operating lease liabilities   (6)   (230)
Net cash used in operating activities   (4,138)   (2,786)
           
INVESTING ACTIVITIES          
Cost of intangible assets   (58)   (210)
Net cash used in investing activities   (58)   (210)
           
FINANCING ACTIVITIES          
Net proceeds of issuance of Series D preferred stock   4,312    - 
Net proceeds of issuance of common stock and warrants   -    8,550 
Warrant exercises   -    2,586 
Net cash provided by financing activities   4,312    11,136 
           
Net increase in cash, cash equivalents and restricted cash   116    8,140 
Cash, cash equivalents and restricted cash at beginning of year   41,614    25,178 
Cash, cash equivalents and restricted cash at end of year  $41,730   $33,318 
           
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows:          
           
Cash and cash equivalents   36,480    33,318 
Restricted cash   5,250    - 
Total cash, cash equivalents and restricted cash shown in condensed statements of cash flows   41,730    33,318 
           
SUPPLEMENTAL CASH FLOW INFORMATION          
Cash paid for taxes  $-   $- 

 

The accompanying notes should be read in conjunction with the financial statements.

 

7
 

 

ADVAXIS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

1. NATURE OF OPERATIONS

 

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm TechnologyTM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

 

  ● Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
  ● Attacking the tumor by generating a strong, cancer-specific T cell response; and
  ● Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

 

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

 

Liquidity and Capital Resources

 

Liquidity and Management’s Plans

 

Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.

 

As of January 31, 2022, the Company had approximately $36.5 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least one year from the issuance of these consolidated financial statements, the actual amount of cash that it will need to operate is subject to many factors.

 

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

 

Basis of Presentation/Estimates

 

The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of January 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

 

8
 

 

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

 

These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

 

Restricted Cash

 

On January 31, 2022, the Company transferred $5,250,000 into an escrow fund to fund a potential Series D preferred stock redemption.

 

Convertible Preferred Stock

 

Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.

 

9
 

 

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

 

   As of January 31, 
   2022   2021 
Warrants   30,225,397    8,014,220 
Series D convertible redeemable preferred stock   20,000,000    - 
Stock options   888,058    1,047,377 
Restricted stock units   -    5,556 
Total   51,113,455    9,067,153 

 

Recent Accounting Standards

 

In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

 

3. PROPERTY AND EQUIPMENT

 

Property and equipment, net consisted of the following (in thousands):

 

   January 31, 2022   October 31, 2021 
Laboratory equipment  $179   $179 
Computer equipment   241    241 
Total property and equipment   420    420 
Accumulated depreciation and amortization   (320)   (302)
Net property and equipment  $100   $118 

 

Depreciation expense for the three months ended January 31, 2022 and 2021 was approximately $18,000 and $192,000, respectively.

 

10
 

 

4. INTANGIBLE ASSETS

 

Intangible assets, net consisted of the following (in thousands):

 

   January 31, 2022   October 31, 2021 
         
Patents  $4,769   $4,836 
Licenses   777    777 
Software   98    98 
Total intangibles   5,644    5,711 
Accumulated amortization   (2,406)   (2,357)
Intangible assets  $3,238   $3,354 

 

The expiration dates of the existing patents range from 2021 to 2039 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of approximately $104,000 and $0 were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended January 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated approximately $70,000 and $67,000 for the three months ended January 31, 2022 and 2021, respectively.

 

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and other products that are in development. However, if a competitor were to gain FDA approval for a similar treatment before the Company or if future clinical trials fail to meet the targeted endpoints, the Company will likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.

 

As of January 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

 

   Fiscal year ending
October 31,		 
     
2022 (Remaining)  $211 
2023   282 
2024   282 
2025   282 
2026   282 
Thereafter   1,899 
Total  $3,238 

 

5. ACCRUED EXPENSES:

 

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

 

   January 31, 2022   October 31, 2021 
         
Salaries and other compensation  $170   $55 
Vendors   1,524    1,968 
Professional fees   237    613 
Other   200    200 
Total accrued expenses  $2,131   $2,836 

 

11
 

 

6. LEASES

 

Operating Leases

 

The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $818,000. The Company wrote off of the remaining right-of-use asset of approximately $4.5 million and lease liability of approximately $5.6 million. After consideration of the termination payment and write off of remaining right-of-use asset and lease liability, the Company recorded a net gain of approximately $0.1 million.

 

On March 25, 2021, the Company entered into a new lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one-year term upon six months written notice to the landlord. This new lease was accounted for as a short-term lease at inception, and the Company elected not to recognize a right-of-use asset and lease liability. In September 2021, the Company exercised its option to renew the lease, extending the lease term until March 25, 2023. Since the renewed lease term exceeds one-year, the lease no longer qualifies for the short-term lease exception, resulting in the recognition of a right-of-use asset and operating lease liability of approximately $43,000.

 

Supplemental balance sheet information related to leases was as follows (in thousands):

 

   January 31, 2022   October 31, 2021 
Operating leases:           
Operating lease right-of-use assets  $33   $40 
           
Operating lease liability  $29   $28 
Operating lease liability, net of current portion   5    12 
Total operating lease liabilities  $34   $40 

 

Supplemental lease expense related to leases was as follows (in thousands):

 

Lease Cost (in thousands)   Statements of Operations Classification   For the Three
Months Ended
January 31, 2022		     For the Three
Months Ended
January 31, 2021		  
Operating lease cost   General and administrative     7       290  
Variable lease cost   General and administrative   $ 9       437  
Total lease expense       $ 16       727  

 

Other information related to leases where the Company is the lessee is as follows:

 

   January 31, 2022   October 31, 2021 
Weighted-average remaining lease term   1.2 years    1.4 years 
Weighted-average discount rate   3.79%   3.79%

 

Supplemental cash flow information related to operating leases was as follows:

 

   For the Three
Months Ended
January 31, 2022		   For the Three
Months Ended
January 31, 2021		 
Cash paid for operating lease liabilities  $7   $324 

 

12
 

 

Future minimum lease payments under non-cancellable leases as of January 31, 2022 were as follows:

 

Fiscal Year ending October 31,    
2022 (Remaining)  $22 
2023   13 
Total minimum lease payments   35 
Less: Imputed interest   (1)
Total  $34 

 

7. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

 

Warrants

 

As of January 31, 2022 and October 31, 2021, there were outstanding and exercisable warrants to purchase 30,225,397 shares of our common stock with exercise prices ranging from $0.30 to $281.25 per share. Information on the outstanding warrants is as follows:

 

Exercise
Price		   Number of Shares
Underlying Warrants		   Expiration Date  Type of Financing
$281.25    25   N/A  Other warrants
$0.25    70,297   July 2024  September 2018 Public Offering
$2.80    327,338   September 2024  July 2019 Public Offering
$0.35    4,578,400   November 2025  November 2020 Public Offering
$0.70    11,244,135   April 2026  April 2021 Registered Direct Offering (Accompanying Warrants)
$0.70    14,005,202   5 years after the date such warrants become exercisable, if ever  April 2021 Private Placement (Private Placement Warrants)
 Grand Total    30,225,397       

 

As of January 31, 2022 and October 31, 2021, the Company had 16,149,898 of its total 30,225,397 outstanding warrants classified as equity (equity warrants).

 

Warrant Liability

 

As of January 31, 2022 and October 31, 2021, the Company had 14,075,499 of its total 30,225,397 outstanding warrants from an April 2021 private offering of common stock and warrants (the “April 2021 Private Placement”) and a September 2018 public offering of common stock and warrants (the “September 2018 Public Offering”) classified as liabilities (liability warrants).

 

The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is 14 days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As of January 31, 2022, the Company did not have sufficient authorized common stock to allow for the issuance of common stock underlying these warrants. The Company did not receive stockholder authorization to increase the authorized shares from 170,000,000 to 300,000,000 shares at the stockholder’s meeting commenced on June 3, 2021. The Company was subsequently required to file a proxy to seek an increase in the number of authorized shares and did not file such a proxy but rather elected to seek a reverse stock split to, among other things, increase the shares available. Accordingly, based on certain indemnification provisions of the securities purchase agreement, the Company concluded that liability classification is warranted. The Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

 

13
 

 

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:

 

   January 31, 2022   October 31, 2021 
Exercise Price  $0.70   $0.70 
Stock Price  $0.136   $0.485 
Expected Term    5.00 years      5.00 years  
Volatility %   108%   106%
Risk Free Rate   1.62%   1.18%

 

The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of January 31, 2021, the down round feature was triggered four times and the exercise price of the warrants were reduced from $22.50 to $0.25. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

 

In measuring the warrant liability for the September 2018 Public Offering warrants at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

 

   January 31, 2022   October 31, 2021 
Exercise Price  $0.25   $0.30 
Stock Price  $0.136   $0.485 
Expected Term   2.61 years     2.87 years  
Volatility %   118%   123%
Risk Free Rate   1.29%   0.77%

 

At January 31, 2022 and October 31, 2021, the fair value of the warrant liability was approximately $1,127,000 and $4,929,000, respectively. For the three months ended January 31, 2022 and 2021, the Company reported income of approximately $3,802,000 and expense of $27,000, respectively, due to changes in the fair value of the warrant liability.

 

8. COMMITMENTS AND CONTINGENCIES

 

Atachbarian

 

On November 15, 2021, a purported stockholder of the Company commenced an action against the Company and certain of its directors in the U.S. District Court for the District of New Jersey, entitled Atachbarian v. Advaxis, Inc., et al., No. 3:21-cv-20006. The plaintiff alleges that the defendants breached their fiduciary duties and violated Section 14(a) and Rule 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder by allegedly failing to disclose certain matters in its Registration Statement on Form S-4 (Commission File No. 333-259065 (the “Registration Statement”) filed in connection with a proposed merger with Biosight Ltd. (the “Previously Proposed Merger”). On December 15, 2021, pursuant to an understanding reached with the plaintiff, the Company made certain other additional disclosures that mooted the demands asserted in the complaint. On December 17, 2021, the plaintiff filed a notice of voluntary dismissal with prejudice. On February 7, 2022, the Company and the plaintiff reached a settlement agreement, which is recorded in accrued expenses in the consolidated balance statement.

 

14
 

 

Purported Stockholder Claims Related to Biosight Transaction

 

Between September 16, 2021, and November 4, 2021, the Company received demand letters on behalf of six purported stockholders of the Company, alleging that the Company failed to disclose certain matters in the Registration Statement, and demanding that the Company disclose such information in a supplemental disclosure filed with the SEC. On October 14, 2021, the Company filed an amendment to the Registration Statement and on November 8, 2021, the Company made certain other additional disclosures that mooted the demands asserted in the above-referenced letters. The six plaintiffs have made a settlement demand. The Company believes it has adequately accrued for a settlement, which is recorded in accrued expenses in the consolidated balance sheet.

 

In addition, the Company received certain additional demands from stockholders asserting that the proxy materials filed by the Company in connection with the Previously Proposed Merger contained alleged material misstatements and/or omissions in violation of federal law. In response to these demands, the Company agreed to make, and did make, certain supplemental disclosures to the proxy materials. At this time, the Company is unable to predict the likelihood of an unfavorable outcome.

 

9. TEMPORARY EQUITY

 

Series D Convertible Preferred Stock Offering

 

On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock (“Series D preferred stock”). The shares to be sold have an aggregate stated value of $5,000,000. Each share of the Series D preferred stock has a purchase price of $4.75, representing an original issue discount of 5% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4,312,000.

 

The Company has called a special meeting of stockholders to consider an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, to effect a reverse stock split of the outstanding shares of common stock by a ratio to be determined by the Board of Directors of the Company within a range to be specified in the proposal put to the stockholders for approval of the Amendment. The investors have agreed in the Purchase Agreement to not transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of the shares of the Series D preferred stock until the reverse stock split and to vote the shares of the Series D preferred stock purchased in the offering in a manner that “mirrors” the proportions on which the shares of common stock (excluding any shares of common stock that are not voted) are voted on the reverse stock split and the Amendment. The Amendment requires the approval of the majority of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. The certificate of designation provides that the Series D preferred stock will have no voting rights, other than the right to vote as a class on certain specified matters, except that each share of Series D preferred stock will have the right to cast 30,000 votes per share of Series D preferred stock on the reverse stock split.

 

The Series D preferred stock can be converted at the option of the holder at any time after the Company has received stockholder approval for a reverse stock split and filed the requisite amendment with the Delaware Secretary of State’s office to effectuate the reverse stock split, subject to beneficial ownership limitations. The Company will be permitted to compel conversion of the Series D preferred stock after the fulfillment of certain conditions and subject to certain limitations. The Series D preferred stock is convertible into shares of Common Stock at a rate of $0.25 per share for the Series D preferred stock. In addition, on or after the reverse stock split date, and subject to the satisfaction of certain conditions, the Company can cause the holder of the Series D Preferred Stock to convert their shares of Series D Preferred Stock, subject to such beneficial ownership limitations.

 

15
 

 

The Series D preferred stock has a liquidation preference over the common stock, and may be redeemed by the investors. Each holder of the Series D preferred stock has the right to cause the Company to redeem all or part of their shares of the Series D preferred stock from the earlier of receipt of stockholder approval of the reverse stock split or 90 days following the original issue date until 120 days following the original issue date (the “Redemption Date”) in cash at a redemption price equal to 105% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares (whether or not earned or declared, but excluding interest on such dividends) up to, but excluding, the Redemption Date. Under certain circumstances, the commencement of the period during which the Series D preferred stock may be redeemed may be extended from 90 days following the original issue date to 135 days following the original issue date, in which case the Redemption Date would be extended to 165 days following the original issue date. Should such extension occur, the redemption price would be increased to an amount equal to 110% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares.

 

The holders of Series D preferred stock will be entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of common stock.

 

The $4.75 million in gross proceeds of the offering are held in an escrow account, along with an additional $500,000 deposited by the Company to cover the aggregate original issue discount as well as the additional amount that would be necessary to fund the 105% redemption price until the expiration of the redemption period for the Series D Preferred Stock, as applicable, subject to the earlier payment to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in escrow will be disbursed to the Company.

 

In connection with the Offering, the Company and the investors entered into a registration rights agreement, pursuant to which the Company is required to file a registration statement with the Securities and Exchange Commission to register for resale the shares that are issued upon the conversion of shares of Series D preferred stock. The registration statement will be filed with the Securities and Exchange Commission on or before the 60th calendar day following the first date on which shares are issued upon the conversion of shares of Series D preferred stock.

 

Since the Series D preferred stock has a redemption feature at the option of the holder, it is classified as temporary equity. At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $4,225,000, which is the $4,312,000 net proceeds less the $87,000 value of the bifurcated preferred stock redemption liability (see below).

 

Preferred Stock Redemption Liability

 

The Company evaluated the preferred stock redemption feature under ASC 815. Since the preferred stock redemption feature is not considered to be clearly and closely related to the preferred stock host and the redemption feature meets the four characteristics of a derivative under ASC 815, the preferred stock redemption feature is required to be bifurcated from the preferred stock host and valued as a liability. The Company utilized a binomial model to calculate the fair value of the preferred stock redemption feature at issuance.

 

In measuring the preferred stock redemption liability at January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

 

   January 31, 2022 
Exercise Price  $0.25 
Stock Price  $0.136 
Volatility %   105%
Risk Free Rate   1.00%

 

At January 31, 2022, the fair value of the preferred stock redemption liability was approximately $87,000.

 

16
 

 

10. STOCKHOLDERS’ EQUITY

 

A summary of the changes in stockholders’ equity for the three months ended January 31, 2022 and 2021 is presented below (in thousands, except share data):

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   Preferred Stock   Common Stock   Additional Paid-In   Accumulated   Total Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2020      -   $     -    78,074,023   $78   $440,840   $(410,738)  $30,180 
Stock-based compensation   -    -    -    -    236    -    236 
Advaxis public offerings, net of offering costs   -    -    30,666,665    31    8,519    -    8,550 
Warrant exercises   -    -    7,390,000    7    2,579    -    2,586 
Net Loss   -    -    -    -    -    (3,977)   (3,977)
Balance at January 31, 2021   -   $-    116,130,688   $116   $452,174   $(414,715)  $37,575 

 

   Preferred Stock   Common Stock   Additional
Paid-In		   Accumulated   Total
Shareholders’		 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2021       -   $       -    145,638,459   $146   $467,342   $(428,600)  $38,888 
Stock-based compensation   -    -    -    -    26    -    26 
Net Loss   -    -    -    -    -    (365)   (365)
Balance at January 31, 2022   -   $-    145,638,459   $146   $467,368   $(428,965)  $38,549 

 

11. SHARE BASED COMPENSATION

 

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

 

   Three Months Ended January 31, 
   2022   2021 
Research and development  $13   $57 
General and administrative   13    179 
Total  $26   $236 

 

Stock Options

 

A summary of changes in the stock option plan for the three months ended January 31, 2022 is as follows:

 

   Shares   Weighted
Average
Exercise Price		   Weighted
Average
Remaining
Contractual Life
In Years		   Aggregate
Intrinsic Value
(in thousands)		 
Outstanding as of October 31, 2021   893,946   $19.32    7.80   $         27 
Cancelled or expired   (5,888)   277.50           
Outstanding as of January 31, 2022   888,058   $17.61    7.55   $- 
Vested and exercisable at January 31, 2022   484,641   $31.80    6.89   $- 

 

17
 

 

The following table summarizes information about the outstanding and exercisable options at January 31, 2022:

 

Options Outstanding     Options Exercisable  
            Weighted     Weighted           Weighted     Weighted  
            Average     Average           Average     Average  
Exercise     Number     Remaining     Exercise     Number     Remaining     Exercise  
Price Range     Outstanding     Contractual     Price     Exercisable     Contractual     Price  
$ .30-$1.00       672,500       8.29     $ 0.54       270,000       8.20     $ 0.50  
$ 1.01-$10.00       55,379       6.80     $ 7.47       54,462       6.79     $ 7.56  
$ 10.01-$100.00       90,432       5.97     $ 29.02       90,432       5.97     $ 29.02  
$ 100.01-$258.30       69,747       3.07     $ 175.51       69,747       3.07     $ 175.51  

 

As of January 31, 2022, there was approximately $125,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.38 years.

 

Potential Acceleration of Stock Options

 

In the event of a merger transaction, similar to the Previously Proposed Merger Agreement, all of the Chief Executive Officer’s 73,777 unvested stock options, pursuant to his employment agreement, would accelerate.

 

12. LICENSING AGREEMENTS

 

OS Therapies LLC

 

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

 

During the three months ended January 31, 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company therefore transferred and OST took full ownership of the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

 

13. FAIR VALUE

 

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

 

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

 

18
 

 

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

 

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2022 and October 31, 2021 (in thousands):

 

   Level 1   Level 2   Level 3   Total 
Fair value measured at January 31, 2022
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,154   $-   $-   $17,154 
Total Financial Assets at Fair Value  $17,154   $-   $-   $17,154 
                     
Financial liabilities at fair value:                    
Preferred stock redemption liability  $-   $-   $87   $87 
Common stock warrant liability, warrants exercisable at $0.25 through September 2024   -    -    7    7 
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    1,120    1,120 
Total financial liabilities at fair value  $-   $-   $1,214   $1,214 

 

   Level 1   Level 2   Level 3   Total 
Fair value measured at October 31, 2021
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,153   $-   $-   $17,153 
Total Financial Assets at Fair Value  $17,153   $-   $-   $17,153 
                     
Financial liabilities at fair value:                    
Common stock warrant liability, warrants exercisable at $0.30 through September 2024  $-   $-   $27   $27 
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    4,902    4,902 
Total financial liabilities at fair value  $-   $-   $4,929   $4,929 

 

The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the three months ended January 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.

 

   Preferred Stock Redemption Liability   Warrant Liabilities   Total 
Fair value at October 31, 2021  $           -   $4,929   $4,929 
Additions   87    -    87 
Change in fair value   -    (3,802)   (3,802)
Fair value at January 31, 2022  $87   $1,127   $1,214 

 

 

19
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis contains forward-looking statements about our plans and expectations of what may happen in the future. Forward-looking statements are based on a number of assumptions and estimates that are inherently subject to significant risks and uncertainties, and our results could differ materially from the results indicated by our forward-looking statements as a result of many known or unknown factors, including, but not limited to, those factors discussed in Part I Item 1A. “Risk Factors” in our 2021 Annual Report on Form 10-K, below in Part II Item 1A. “Risk Factors” of this Form 10-Q and in the “Cautionary Note Regarding Forward-Looking Statements” set forth at the beginning of this report.

 

You should read the following discussion and analysis in conjunction with the unaudited financial statements, and the related footnotes thereto, appearing elsewhere in this Form 10-Q, and in conjunction with management’s discussion and analysis and the audited financial statements included in our Annual Report on Form 10-K. In addition, we intend to use our media and investor relations website (www.advaxis.com/investor-relations), SEC filings, press releases, public conference calls and webcasts to communicate with the public about Advaxis, its services and other issues.

 

Overview

 

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm Technology antigen delivery products based on a platform technology that utilizes live attenuated Listeria monocytogenes, or Lm, bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy by accessing and directing antigen presenting cells to stimulate anti-tumor T cell immunity, stimulate and activate the innate immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the Tumor Microenvironment, or TME, to enable the T cells to attack tumor cells.

 

The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, our product candidates (i.e., ADXS-PSA, ADXS-503 and ADXS-504) have the potential to optimize checkpoint performance, while having a generally well-tolerated safety profile, and most of our product candidates have an expected low cost of goods.

 

Advaxis is currently winding down or has wound down clinical studies of Lm Technology immunotherapies in three program areas:

 

  ● Human Papilloma Virus (“HPV”)-associated cancers
  ● Personalized neoantigen-directed therapies
  ● Human epidermal growth factor receptor-2 (HER-2) associated cancers

 

All these clinical program areas are anchored in the Company’s Lm TechnologyTM, a unique platform designed for its ability to safely and effectively target various cancers in multiple ways. While we are currently winding down clinical studies of Lm Technology immunotherapies in these three program areas, our license agreements continue with OS Therapies, LLC for ADXS-HER2 and with Global BioPharma, or GBP, for the exclusive license for the development and commercialization of AXAL in Asia, Africa, and the former USSR territory, exclusive of India and certain other countries.

 

Recent Developments

 

COVID-19 Impact

 

The global health crisis caused by the ongoing novel coronavirus (“COVID-19”) pandemic and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination efforts, remains uncertain and cannot be predicted with confidence. In addition, a new Omicron variant of COVID-19, which appears to be the most transmissible variant to date, has spread globally. The continued impact of the pandemic cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among the population, the occurrence and spread of additional variants of COVID-19, the effectiveness of COVID-19 vaccines against current or future variants and the response by governmental bodies and regulators.

 

20
 

 

In response to COVID-19, the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development or drug production of our drug candidates by third parties. We continue to monitor the COVID-19 pandemic and take steps intended to mitigate the potential risks to our workforce and our operations. The COVID-19 pandemic has, and may continue to, directly or indirectly affect the pace of enrollment in our clinical trials as patients may avoid or may not be able to travel to healthcare facilities and physicians’ offices unless due to a health emergency and clinical trial staff can no longer get to the clinic. Nonetheless, thus far, the COVID-19 pandemic has not had a significant impact on our business or results of operations. However, we remain in contact with the clinical sites in our study and are in discussion with additional sites to combat any potential impact in enrollment. We are unable to determine or predict the extent, duration or scope of the overall impact of the COVID-19 pandemic on our business, operations, financial condition or liquidity.

 

Financings

 

On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock. The shares to be sold have an aggregate stated value of $5,000,000. Each share of the Series D preferred stock has a purchase price of $4.75, representing an original issue discount of 5% of the stated value. The shares of Series D preferred stock are convertible into shares of the Company’s common stock, upon the occurrence of certain events, at a conversion price of $0.25 per share. The conversion, at the option of the stockholder, may occur at any time following the receipt of the stockholders’ approval for a reverse stock split. The Company will be permitted to compel conversion of the Series D preferred stock after the fulfillment of certain conditions and subject to certain limitations. The Series D preferred stock will also have a liquidation preference over the common stock, and may be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value. The Company and the holders of the Series D preferred stock will also enter into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series D preferred stock. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4.3 million.

 

Results of Operations for the Three Months Ended January 31, 2022 and 2021

 

Revenue

 

Revenue was $0 for the three months ended January 31, 2022 compared to $1,615,000 for the three months ended January 31, 2021. In the prior period, we recognized royalty payments from OST.

 

Research and Development Expenses

 

We invest in research and development to advance our Lm technology through our pre-clinical and clinical development programs. Research and development expenses for the three months ended January 31, 2022 and January 31, 2021 were categorized as follows (in thousands):

 

   Three Months Ended
January 31,		   Increase
(Decrease)		 
   2022   2021   $   % 
                 
Hotspot/Off-the-Shelf therapies  $1,000   $1,200   $(200)   (17)%
Prostate cancer   55    42    13    31%
HPV-associated cancers   (39)   531    (570)   (107)%
Personalized neoantigen-directed therapies   -    132    (132)   (100)%
Other expenses   638    665    (27)   (4)%
Total research & development expense  $1,654   $2,570   $(916)   (36)%
                     
Stock-based compensation expense included in research and development expense  $13   $57   $(44)   (77)%

 

21
 

 

Hotspot/Off-the-Shelf Therapies (ADXS-HOT)

 

Research and development costs associated with our hotspot mutation-based therapy for the three months ended January 31, 2022 decreased approximately 17% to $1,000,000 compared to the same period in 2021. The decrease is attributable to a slowdown in patient enrollment in the HOT-503 study.

 

Prostate Cancer (ADXS-PSA)

 

Research and development costs associated with our prostate cancer therapy for the three months ended January 31, 2022 increased approximately $13,000, or 31%, compared to the same period in 2021. The increase is immaterial. We do not anticipate that we will continue to incur significant costs associated with the wind down of the study.

 

HPV-Associated Cancers (AXAL)

 

The majority of the HPV-associated research and development costs include clinical trial and other related costs associated with our AXAL programs in cervical and head and neck cancers. HPV-associated costs for the three months ended January 31, 2022 decreased approximately $570,000, or 107%, compared to the same period in 2021. The decrease is attributable to wind down costs associated with the closure of our Phase 3 AIM2CERV study in high-risk locally advanced cervical cancer, as well as credit memos issued by our contract research organization associated with the closeout of our Phase 1/2 study in head and neck cancer. We do not anticipate that we will continue to incur significant costs associated with the wind down of our Phase 3 AIM2CERV study.

 

Personalized Neoantigen-Directed Therapies (ADXS-NEO)

 

Research and development costs associated with personalized neoantigen-directed therapies for the three months ended January 31, 2022 decreased approximately $132,000, or 100%, compared to the same period in 2021. The decrease is attributable to wind down costs associated with the termination of our ADXS-NEO study. We do not anticipate that we will continue to incur significant costs associated with the wind down of the study.

 

Other Expenses

 

Other expenses include salary and benefit costs, stock-based compensation expense, professional fees, laboratory costs and other internal and external costs associated with our research & development activities. Other expenses for the three months ended January 31, 2022 decreased approximately $27,000, or 4%, compared to the same period in 2021. The decrease was immaterial.

 

General and Administrative Expenses

 

General and administrative expenses primarily include salary and benefit costs and stock-based compensation expense for employees included in our finance, legal and administrative organizations, outside legal and professional services, and facilities costs. General and administrative expenses for the three months ended January 31, 2022 and January 31, 2021 were as follows (in thousands):

 

   Three Months Ended
January 31,		   Increase
(Decrease)		 
   2022   2021   $   % 
                 
General and administrative expense  $2,510   $3,008   $(498)   (17)%
                     
Stock-based compensation expense included in general and administrative expense  $13   $179   $(166)   (93)%

 

22
 

 

General and administrative expenses for the three months ended January 31, 2022 decreased approximately $498,000, or 17%, compared to the same period in 2021. This decrease primarily relates to (1) a decrease in personnel costs due to decreases in stock compensation and bonus accruals (2) decreases in rent, utilities and depreciation due to the termination of our office lease at our former location and (3) a decrease in legal costs. These decreases were partially offset by increases in (1) proxy solicitation fees related to the Previously Proposed Merger and (2) charges related to the abandonment of non-strategic intellectual property.

 

Changes in Fair Values

 

For the three months ended January 31, 2022, we recorded non-cash income from a decrease in the fair value of the warrant liability of approximately $3,802,000. The decrease in the fair value of liability warrants resulted from resulted from a decrease in our share price from $0.49 at October 31, 2021 to $0.14 at January 31, 2022.

 

For the three months ended January 31, 2021, we recorded non-cash loss from an increase in the fair value of the warrant liability of approximately $27,000. The increase in the fair value of liability warrants resulted from an increase in our share price from $0.34 at October 31, 2020 to $0.73 at January 31, 2021.

 

Liquidity and Capital Resources

 

Management’s Plans

 

Similar to other development stage biotechnology companies, our products that are being developed have not generated significant revenue. As a result, we have historically suffered recurring losses and we have required significant cash resources to execute our business plans. These losses are expected to continue for the foreseeable future.

 

Historically, the Company’s major sources of cash have comprised proceeds from various public and private offerings of its securities (including common stock), debt financings, clinical collaborations, option and warrant exercises, income earned on investments and grants, and interest income. From October 2013 through January 31, 2022, the Company raised approximately $339.4 million in gross proceeds from various public and private offerings of our common stock. The Company has sustained losses from operations in each fiscal year since our inception, and we expect losses to continue for the indefinite future. As of January 31, 2022 and October 31, 2021, the Company had an accumulated deficit of approximately $429.0 million and $428.6 million, respectively, and stockholders’ equity of approximately $38.5 million and $38.9 million, respectively.

 

The COVID-19 pandemic has negatively affected the global economy and created significant volatility and disruption of financial markets. An extended period of economic disruption could negatively affect the Company’s business, financial condition, and access to sources of liquidity. As of January 31, 2022, the Company had approximately $36.5 million in cash and cash equivalents. The actual amount of cash that the Company will need to continue operating is subject to many factors.

 

The Company recognizes that it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that the Company will be able to obtain financing on terms acceptable to it or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations. The Company believes it has sufficient capital to fund its obligations, as they become due, in the ordinary course of business into the second fiscal quarter of 2024. The Company based this estimate on assumptions that may prove to be wrong, and we could use available capital resources sooner than currently expected.

 

Cash Flows

 

Operating Activities

 

Net cash used in operating activities includes spending associated with our clinical trial programs and general and administrative activities. Net cash used in operating activities was approximately $4,138,000 for the three months ended January 31, 2022 compared to $2,786,000 for the three months ended January 31, 2021. The Company received $1,615,000 in royalty payments from OST in the prior period.

 

23
 

 

Investing Activities

 

Net cash used in investing activities was approximately $58,000 for three months ended January 31, 2022 compared to $210,000 for the three months ended January 31, 2021. The decrease is a result of the abandonment of certain non-strategic intellectual property in the current period.

 

Financing Activities

 

Net cash provided by financing activities was approximately $4,312,000 for the three months ended January 31, 2022 compared to $11,136,000 for the three months ended January 31, 2021. On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock. The shares to be sold have an aggregate stated value of $5,000,000. Each share of the Series D preferred stock has a purchase price of $4.75, representing an original issue discount of 5% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4.3 million. The shares of Series D preferred stock are convertible into shares of the Company’s common stock, upon the occurrence of certain events, at a conversion price of $0.25 per share. The conversion, at the option of the stockholder, may occur at any time following the receipt of the stockholders’ approval for a reverse stock split. The Series D preferred stock will also have a liquidation preference over the common stock, and may be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value.

 

In November 2020, the Company closed on a public offering of 30,666,665 shares of its common stock at a public offering price of $0.30 per share. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5 million. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 15,333,332 shares of common stock. The warrants have an exercise price per share of $0.35, are exercisable immediately and will expire five years from the date of issuance. During the three months ended January 31, 2021, warrant holders from the Company’s November 2020 offering exercised 7,390,000 warrants in exchange for 7,390,000 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregate proceeds of approximately $2.6 million.

 

Off-Balance Sheet Arrangements

 

As of January 31, 2022, we had no off-balance sheet arrangements.

 

Critical Accounting Estimates

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and related disclosures in the financial statements. Management considers an accounting estimate to be critical if:

 

  ● it requires assumptions to be made that were uncertain at the time the estimate was made, and
     
  ● changes in the estimate or different estimates that could have been selected could have material impact in our results of operations or financial condition.

 

While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances, actual results could differ from those estimates and the differences could be material. The most significant estimates impact the following transactions or account balances: warrant liability valuation, preferred stock redemption liability valuation and impairment of intangibles.

 

See Note 2 to our condensed consolidated financial statements for a discussion of our significant accounting policies.

 

24
 

 

Recently Issued Accounting Standards Not Yet Effective or Adopted

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

At January 31, 2022, we had approximately $36.5 million in cash and cash equivalents, which consisted primarily of bank deposits and money market funds. Our investment policy and strategy are focused on preservation of capital and supporting our liquidity requirements. We use a combination of internal and external management to execute our investment strategy and achieve our investment objectives. We typically invest in highly-rated securities (such as money market funds), and our investment policy generally limits the amount of credit exposure to any one issuer. The policy requires investments generally to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations of interest income have not been significant.

 

We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our financial statements.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and interim principal financial officer of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (“the Exchange Act”). Based upon this evaluation, our chief executive officer and principal financial officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (1) accumulated and communicated to our management, including our chief executive officer, as appropriate to allow timely decisions regarding required disclosure; and (2) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

 

Changes in Internal Control over Financial Reporting

 

During the quarter ended January 31, 2022, there were no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

Limitations on Effectiveness of Controls

 

Our management, including our Principal Executive, Financial and Accounting Officers, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

The Company is from time to time involved in legal proceedings in the ordinary course of our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations. For more information regarding legal proceedings involving the Company, please see Note 10 – Commitments and Contingencies to our condensed consolidated financial statements.

 

25
 

 

Item 1A. Risk Factors

 

Our business and financial results are subject to numerous risks and uncertainties. As a result, the risks and uncertainties discussed in Part I, Item 1A. Risk Factors in our annual report on Form 10-K for the fiscal year ended October 31, 2021, (as filed with the SEC on February 14, 2022) should be carefully considered.

 

Item 6. Exhibits

 

Exhibit No.   Description
     
3.1   Certificate of Correction to the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.2   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.3   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.3 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.4   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.4 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.5   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.5 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.6   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.6 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.7   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.7 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.8   Form of Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Redeemable Preferred Stock, Incorporated by reference to Exhibit 3.8 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.9   Amendment No. 2 to the Second Amended and Restated By-Laws of Advaxis, Inc., Incorporated by reference to Exhibit 3.9 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.10   Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Redeemable Preferred Stock, Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the SEC on February 1, 2022

 

26
 

 

10.1   Termination Letter from Advaxis, Inc. to Biosight LTD., dated December 30, 2021, Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on December 30, 2021.
     
10.2   Form of Securities Purchase Agreement between Advaxis, Inc. and the investors thereto, dated January 27, 2022, Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on January 28, 2022.
     
10.3   Form of Registration Rights Agreement by and among Advaxis, Inc. and the investors named therein, Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
31.1*   Certification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002
     
32.2*   Certification of Principal Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   XBRL INSTANCE DOCUMENT
     
101.SCH   XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
     
101.CAL   XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
     
101.DEF   XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
     
101.LAB   XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
     
101.PRE   XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

 

* Filed herewith.

 

27
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Corporation has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

March 17, 2022

 

  ADVAXIS, INC.
     
  By: /s/ Igor Gitelman
  Name:  Igor Gitelman
  Title: Chief Accounting Officer, VP of Finance

 

  By: /s/ Kenneth Berlin
  Name:  Kenneth Berlin
  Title: President, Chief Executive Officer and Interim Chief Financial Officer

 

28
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Ayala Pharmaceuticals (CE)
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Ayala Pharmaceuticals (CE)